加载中
NASDAQHealthcareBiotechnology
最新数据
US$2.8559
+US$0.0059 · +0.21%
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
常规交易时段
US$2.8559
+US$0.0059 · +0.21%
盘中时间采用ET。市场数据可能有所延迟。
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
日内区间
当前US$2.8559
52周区间
当前US$2.8559
盘中时间采用ET。市场数据可能有所延迟。
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
日内区间
当前US$2.8559
52周区间
当前US$2.8559
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 122.5万 USD | — | — | — | — |
| 销货成本 | 50.5万 USD | 5000 USD | 5000 USD | 4000 USD | 2000 USD |
| 毛利 | 72万 USD | −5000 USD | −5000 USD | −4000 USD | −2000 USD |
| 研究与开发 | 377.7万 USD | 619.9万 USD | 1337.1万 USD | 1702.7万 USD | 2025.7万 USD |
| 销售、一般及管理费用 | 1306.1万 USD | 1350万 USD | 1421.1万 USD | 2730.4万 USD | 7494.2万 USD |
| 营业费用 | 1694.4万 USD | 1969.9万 USD | 2758.2万 USD | 4433.1万 USD | 9519.9万 USD |
| 利息收入 | 1.2万 USD | 4.4万 USD | 49.4万 USD | 24.9万 USD | 18 USD |
| 利息支出 | 67.1万 USD | 107.9万 USD | 12万 USD | — | 1.8万 USD |
| 折旧和摊销 | 14.3万 USD | 5000 USD | 5000 USD | 4000 USD | 2000 USD |
| 营业利润 | −1622.4万 USD | −1970.4万 USD | −2758.7万 USD | −4433.5万 USD | −9520.1万 USD |
| 净利润 | −2862.2万 USD | −2512.6万 USD | −3015万 USD | −3975.4万 USD | −9306.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$2.00
下跌空间 29.97%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年4月2日 | 1:10 | — | — |
已生效 2024年4月2日
1:10
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI440.95万0.00%2.3万亿 USD0.03%US$381.52-0.11%
AdvisorShares Psychedelics ETFPSIL213.13万4.55%4685.29万 USD1.84%US$21.21-2.55%
Vanguard Extended Market ETFVXF109.23万0.00%954亿 USD0.05%US$233.61-0.59%
iShares Micro-Cap ETFIWC30.44万0.02%13.17亿 USD0.60%US$181.82-0.64%Vanguard Morningstar Total Stock Market ETFVTIAdvisorShares Psychedelics ETFPSILVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
